Rotavirus vaccination is a protective factor for adverse outcomes in primary intussusception: a single-center retrospective study.

IF 1.5 4区 医学 Q2 PEDIATRICS
Translational pediatrics Pub Date : 2024-06-30 Epub Date: 2024-06-27 DOI:10.21037/tp-24-109
Min Du, Lihong Shang, Xin Li, Rongna Huang, Haibo Yao, Sheng Yang, Sujing Zhao, Libing Zhang, Xiaoli Xie
{"title":"Rotavirus vaccination is a protective factor for adverse outcomes in primary intussusception: a single-center retrospective study.","authors":"Min Du, Lihong Shang, Xin Li, Rongna Huang, Haibo Yao, Sheng Yang, Sujing Zhao, Libing Zhang, Xiaoli Xie","doi":"10.21037/tp-24-109","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The clinical features and prognosis of intussusception in children vaccinated against rotavirus were undefined. Hence, we conducted the study to explore the clinical characteristics and outcomes of primary intussusception patients who received rotavirus vaccine.</p><p><strong>Methods: </strong>A single-center retrospective study was performed in 327 primary intussusception patients between January 2019 and December 2021. Of these, 168 were vaccinated against rotavirus and 159 were not, the latter serving as the control group. Data on patients' clinical characteristics, commonly used inflammatory biomarkers, treatment, and outcomes were collected and evaluated.</p><p><strong>Results: </strong>Most of the vaccination group received pentavalent rotavirus vaccine produced by Merck, USA (89.88%). There were no differences in demographic characteristics, time from onset to hospital attendance, clinical symptoms and signs between the vaccination group and the control group. The success rate of air enema reduction in the vaccination group was higher than that in the control group (98.21% <i>vs</i>. 88.68%, q=0.01). The vaccination group had lower rates of surgery and complication (1.79% <i>vs</i>. 11.32%, q=0.008; 2.98% <i>vs</i>. 12.58%, q=0.006). Both platelet-lymphocyte ratio (PLR) and C-reactive protein (CRP) levels were lower in the vaccinated group (q=0.02, q=0.004). Higher CRP level [odds ratio (OR): 1.635; 95% confidence interval (CI): 1.248-2.143; P=0.006] and the longer time from onset to hospital attendance (OR: 3.040; 95% CI: 2.418-12.133; P=0.01) were associated with increased adverse events. Rotavirus vaccination (OR: 0.527; 95% CI: 0.103-0.751; P=0.02) was associated with a reduction in the probability of adverse events.</p><p><strong>Conclusions: </strong>Adverse events such as surgery and complications were lower in the vaccination group. Rotavirus vaccination was an independent protective factor for adverse events in patients with primary intussusception.</p>","PeriodicalId":23294,"journal":{"name":"Translational pediatrics","volume":"13 6","pages":"877-888"},"PeriodicalIF":1.5000,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tp-24-109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The clinical features and prognosis of intussusception in children vaccinated against rotavirus were undefined. Hence, we conducted the study to explore the clinical characteristics and outcomes of primary intussusception patients who received rotavirus vaccine.

Methods: A single-center retrospective study was performed in 327 primary intussusception patients between January 2019 and December 2021. Of these, 168 were vaccinated against rotavirus and 159 were not, the latter serving as the control group. Data on patients' clinical characteristics, commonly used inflammatory biomarkers, treatment, and outcomes were collected and evaluated.

Results: Most of the vaccination group received pentavalent rotavirus vaccine produced by Merck, USA (89.88%). There were no differences in demographic characteristics, time from onset to hospital attendance, clinical symptoms and signs between the vaccination group and the control group. The success rate of air enema reduction in the vaccination group was higher than that in the control group (98.21% vs. 88.68%, q=0.01). The vaccination group had lower rates of surgery and complication (1.79% vs. 11.32%, q=0.008; 2.98% vs. 12.58%, q=0.006). Both platelet-lymphocyte ratio (PLR) and C-reactive protein (CRP) levels were lower in the vaccinated group (q=0.02, q=0.004). Higher CRP level [odds ratio (OR): 1.635; 95% confidence interval (CI): 1.248-2.143; P=0.006] and the longer time from onset to hospital attendance (OR: 3.040; 95% CI: 2.418-12.133; P=0.01) were associated with increased adverse events. Rotavirus vaccination (OR: 0.527; 95% CI: 0.103-0.751; P=0.02) was associated with a reduction in the probability of adverse events.

Conclusions: Adverse events such as surgery and complications were lower in the vaccination group. Rotavirus vaccination was an independent protective factor for adverse events in patients with primary intussusception.

轮状病毒疫苗接种是原发性肠套叠不良后果的保护因素:一项单中心回顾性研究。
背景:接种轮状病毒疫苗的儿童肠套叠的临床特征和预后尚未明确。因此,我们开展了这项研究,探讨接种轮状病毒疫苗的原发性肠套叠患者的临床特征和预后:2019年1月至2021年12月期间,我们对327名原发性肠套叠患者进行了单中心回顾性研究。其中,168 人接种了轮状病毒疫苗,159 人未接种,后者作为对照组。研究人员收集并评估了患者的临床特征、常用炎症生物标志物、治疗和结果等数据:大多数接种组接种了美国默克公司生产的五价轮状病毒疫苗(89.88%)。接种组与对照组在人口统计学特征、发病到入院时间、临床症状和体征方面无差异。接种组减少空气灌肠的成功率高于对照组(98.21% 对 88.68%,q=0.01)。疫苗接种组的手术率和并发症发生率较低(1.79% 对 11.32%,q=0.008;2.98% 对 12.58%,q=0.006)。接种疫苗组的血小板淋巴细胞比率(PLR)和C反应蛋白(CRP)水平均较低(q=0.02,q=0.004)。较高的 CRP 水平[比值比 (OR):1.635;95% 置信区间 (CI):1.248-2.143;P=0.006]和从发病到入院就诊的时间较长(OR:3.040;95% CI:2.418-12.133;P=0.01)与不良事件增加有关。接种轮状病毒疫苗(OR:0.527;95% CI:0.103-0.751;P=0.02)与不良事件发生概率的降低有关:结论:接种疫苗组的手术和并发症等不良事件发生率较低。轮状病毒疫苗接种是原发性肠套叠患者不良事件的独立保护因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Translational pediatrics
Translational pediatrics Medicine-Pediatrics, Perinatology and Child Health
CiteScore
4.50
自引率
5.00%
发文量
108
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信